Nontuberculous Mycobacterial (NTM) Infections Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Nontuberculous Mycobacterial (NTM) Infections Epidemiology Forecast Report Coverage

Expert Market Research's “Nontuberculous Mycobacterial (NTM) Infections Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of nontuberculous mycobacterial (NTM) infections. It projects the future incidence and prevalence rates of nontuberculous mycobacterial (NTM) infection cases across various populations. The study covers age, gender, and type as major determinants of the nontuberculous mycobacterial (NTM) infections population. The report highlights patterns in the prevalence of nontuberculous mycobacterial (NTM) infections over time and projects future trends based on multiple variables.

Nontuberculous Mycobacterial (NTM) Infections Understanding: Disease Overview

Nontuberculous mycobacterial (NTM) infections are caused by environmental mycobacteria distinct from mycobacterium tuberculosis. These organisms are commonly found in soil and water and can cause pulmonary, skin, or disseminated infections, particularly in immunocompromised individuals or those with underlying lung disease. Mycobacterium avium complex (MAC) is the most prevalent species globally. Clinical manifestations vary but often include chronic cough, fatigue, and weight loss in pulmonary disease. Diagnosis requires microbiological confirmation through culture and molecular testing, as symptoms may resemble tuberculosis or other chronic respiratory conditions.

Nontuberculous Mycobacterial (NTM) Infections Epidemiology Perspective

The nontuberculous mycobacterial (NTM) infections epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the nontuberculous mycobacterial (NTM) infections epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for nontuberculous mycobacterial (NTM) infections and their trends. The nontuberculous mycobacterial (NTM) infections detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• NTM infections have risen worldwide, with pooled prevalence in adults with non-cystic fibrosis bronchiectasis estimated at approximately 10%, varying significantly by region. Mycobacterium avium complex (MAC) is the most common species.
• NTM pulmonary disease predominantly affects older adults, with the majority of cases occurring in individuals over 60 years of age, reflecting age as a key risk factor globally.
• Gender distribution varies regionally; in some areas, females exhibit higher NTM incidence, while in others, males predominate, indicating demographic differences across geographic populations.
• Nontuberculous Mycobacterial (NTM) infections are often underdiagnosed or misclassified, and most countries lack mandatory reporting, resulting in limited population-level data and uncertainty in global prevalence estimates.

Read more about this report - Request a Free Sample

Country-wise Nontuberculous Mycobacterial (NTM) Infections Epidemiology Segment

The nontuberculous mycobacterial (NTM) infections epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Nontuberculous Mycobacterial (NTM) infections are an emerging health concern in the United States, with pulmonary disease incidence estimated at 20.1 cases per 100,000 population. Incidence has increased steadily over the past decade, particularly in the South. Older adults, especially those aged 80 years and above, are disproportionately affected, and women exhibit a 1.4-2.0-fold higher incidence than men. In Germany, NTM pulmonary disease incidence from respiratory samples is estimated at approximately 4.5–4.9 cases per 100,000 population. These trends underscore the growing burden of NTM infections among vulnerable populations, highlighting the importance of enhanced surveillance, early diagnosis, and targeted interventions to manage and mitigate disease impact.

Nontuberculous Mycobacterial (NTM) Infections: Treatment Overview

Treatment of NTM infections depends on species identification and disease severity. Pulmonary MAC infections are typically managed with prolonged multidrug regimens, including macrolides, ethambutol, and rifamycins, with therapy often extending for at least 12 months beyond culture conversion. Rapidly growing mycobacteria may require different antibiotic combinations guided by susceptibility testing. Surgical intervention may be considered in localized, refractory pulmonary disease. Management is complex due to antibiotic resistance, drug toxicity, and high relapse rates. Individualized treatment plans and long-term monitoring are essential, particularly in patients with structural lung disease or compromised immunity.

Key Questions Answered

• What are the key findings of nontuberculous mycobacterial (NTM) infections epidemiology in the 8 major markets?
• What will be the total number of patients with nontuberculous mycobacterial (NTM) infections across the 8 major markets during the forecast period?
• What was the country-wise nontuberculous mycobacterial (NTM) infections epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of nontuberculous mycobacterial (NTM) infections during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of nontuberculous mycobacterial (NTM) infections during the forecast period of 2026-2035?
• What are the currently available treatments for nontuberculous mycobacterial (NTM) infections?
• What are the disease risks, signs, symptoms, and unmet needs of nontuberculous mycobacterial (NTM) infections?

Scope of the Nontuberculous Mycobacterial (NTM) Infections Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of nontuberculous mycobacterial (NTM) infections based on several factors.
• Nontuberculous Mycobacterial (NTM) Infections Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The nontuberculous mycobacterial (NTM) infections report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Nontuberculous Mycobacterial Infections Pipeline Analysis